米氮平结合潘立酮治疗高血压合并抑郁焦虑症患者的临床效果

Clinical effect of Mitrazapine combined with paliperidone in treatment of hypertensive patients with depression anxiety

目的探讨米氮平与潘立酮联合治疗对高血压合并抑郁焦虑症患者尿蛋白的影响。方法选取2014年1月到2016年1月于我院就诊的高血压合并抑郁焦虑症患者180例,将患者按照入院编号,随机分为三组,A、B、C三组各60例患者,A组患者采用米氮平30mg,1/次天治疗;B组患者采用潘立酮150mg,1/次天治疗;C组患者采用联合治疗法,疗程均为2周,治疗后观察三组患者尿蛋白肾功改善情况及降压效果。结果 C组患者在接受治疗后,平均尿微量白蛋白含量(19.86±5.1mmol.L^(-1))vs.(38.5±5.0 mmol.L^(-1))、(37.6±5.0 mmol.L^(-1)),β2-微球蛋白含量(0.50±1.5mg/L)vs.(0.85±1.0mg/L)、(0.73±1.5mg/L)和平均血压值(115.6±10.5mm Hg)vs.(130.2±12.2 mm Hg)、(135.5±10.5mm Hg)均低于A组患者和B组患者,差异均有统计学意义(P<0.05)。结论米氮平结合潘立酮治疗高血压合并抑郁焦虑症能有效改善患者的尿蛋白含量及血压状态,获得理想治疗效果。

Objective To investigate the effects of mirtazapine with paliperidone in treatment of protein nuria in hypertensive patients with depression and anxiety. Methods 180 consecutive hypertensive patients with depression and anxiety were recruited from July2014 to January 2016 in our hospital,they were randomly divided into three different subgroups ：A group receivedmitrazapine drug;B group received paliperidone drug;C group received therapy combined with mirtazapine and paliperidone drug.2 weeks after treatment,compared the urinary protein of three groups of hypertensive patients with anxiety and depression and improve the evaluation. Results After treatment,the mean levels of urine trace albumin（19.86±5.1mmol.L-1）vs.（38.5±5.0mmol.L-1）,（37.6±5.0mmol.L-1）,β2-microglobulin（0.50±1.5mg/L）vs.（0.85±1.0mg/L）,（0.73±1.5mg/L）and pressure value（115.6±10.5mm Hg）vs.（130.2±12.2mm Hg）,（135.5±10.5mm Hg）in the Group C,were significantly lower than the A group and the B group,the differences were statistically significant（P〈0.05）. Conclusion Mirtazapine combination of paliperidone in treatment of hypertensive patients with depression and anxiety disorders can effectively reduce the urinary protein degree,improve the quality of life of patients,in clinical application.